ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "antiphospholipid syndrome"

  • Abstract Number: 0112 • ACR Convergence 2024

    Efforts to Harmonize ELISA and Non-ELISA Anticardiolipin and Anti-β2-glycoprotein-I Levels Based on ISTH SSC LA/aPL and APS ACTION International Multicenter Cohorts

    Arne Vandevelde1, Pierluigi Meroni2, Hannah Cohen3, Danieli Andrade4, Olga Amengual5, TATSUYA ATSUMI5, Angela Tincani6, H Michael Belmont7, Maria Borghi8, David Branch9, Ricard Cervera10, Guilherme Ramires de Jesús11, Paul Fortin12, Jean-Christophe Gris13, Claudia Grossi8, Jason Knight14, Gary W. Moore15, Jacek Musiał16, Michelle Petri17, Esther Rodriguez-Almaraz18, Diana Paredes-Ruiz19, Robert Roubey20, Anne Tebo21, Maria Tektonidou22, Denis WAHL23, Stéphane Zuily23, Rohan Willis24, Vittorio Pengo25, Maria Laura Bertolaccini26, Doruk Erkan27 and Katrien Devreese1, 1Department of Diagnostic Sciences, Ghent University and Coagulation Laboratory, Ghent University Hospital, Ghent, Belgium, 2IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, 3University College London Hospitals NHS Foundation Trust, London, United Kingdom, 4University of São Paulo, São Paulo, SP, Brazil, 5Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 6ASST Spedali Civili-University of Brescia, Brescia, Italy, 7NYU School of Medicine, New York, NY, 8Immunorheumatology research laboratory, IRCCS Istituto Auxologico, Milan, Italy, 9University of Utah and Intermountain Healthcare, Salt Lake City, UT, 10Hospital Clinic de Barcelona, Barcelona, Spain, 11Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 12Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 13Department of Hematology, CHU Nîmes, Univ Montpellier, Nîmes, France and Department of Hematology, Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France and UMR UA11 INSERM IDESP - Montpellier University, France and Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 14University of Michigan, Ann Arbor, MI, 15Specialist Haemostasis Unit, Addenbrooke's Hospital, Cambridge, United Kingdom and Department of Natural Sciences, Middlesex University, London, United Kingdom, 16Department of Internal Medicine, Jagiellonian University Medical College, Kraków, Poland, 17Johns Hopkins University School of Medicine, Timonium, MD, 18Hospital Universitario 12 de Octubre, Madrid, Spain, 19Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, 20Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 21Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 22National and Kapodistrian University of Athens, Athens, Greece, 23Lorraine University, Nancy, France, 24University of Texas Medical Branch, Galveston, TX, 25Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, 26King's College London, London, United Kingdom, 27Hospital for Special Surgery, New York, NY

    Background/Purpose: Correlation of numerical values between the low, moderate, and high (L, M,H) levels of enzyme-linked immunosorbent assay (ELISA) and non-ELISA platforms for anticardiolipin antibody…
  • Abstract Number: 0128 • ACR Convergence 2024

    Damage Index in Patients with Thrombotic Antiphospholipid Syndrome (DIAPS) Version 2.0: One Single Center Pilot Study

    Laura Aline Martinez-Martinez1, Mary-Carmen Amigo2 and María Victoria Goycochea Robles3, 1Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico, 2ABC Medical Center, Mexico City, Estado de México, Mexico, 3Universidad Nacional Autonoma de Mexico, Mexico city, Distrito Federal, Mexico

    Background/Purpose: Antiphospholipid antibody syndrome is the main acquired thrombophilia in the rheumatological area. It is characterized by thrombotic events and obstetric morbidity associated with the…
  • Abstract Number: 2374 • ACR Convergence 2024

    Characteristics, Treatment Responses and Prognosis in a Single Center Cohort of SLE Patients with Thrombocytopenia

    Omer Uludag1, Sarvan Aghamuradov1, Cansu Erel Gezegen2, Marjan Jabbarli2, Ismat Habibov2, Ahmet Oguz Celik2, Yasemin Yalcinkaya1, Ahmet Gul1, Murat Inanc1 and Bahar Artim Esen1, 1Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey

    Background/Purpose: Thrombocytopenia has been reported at frequencies ranging from 10 to 40 % in different cohorts. Treatment can be challenging and due to its considerable…
  • Abstract Number: 0113 • ACR Convergence 2024

    Plasma Proteomics Analysis Identifies Thromboinflammatory Signature Associated with Clinical Antiphospholipid Syndrome: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

    Alexander Pine1, Vittorio Pengo2, Savino Sciascia3, Nina Kello4, Rosario Lopez Pedrera5, H Michael Belmont6, David Branch7, Laura Andreoli8, Michelle Petri9, Ricard Cervera10, Jason Knight11, Pierluigi Meroni12, Hannah Cohen13, Rohan Willis14, Maria Laura Bertolaccini15, Alfred Lee16, Doruk Erkan17 and Anish Sharda16, 1Yale School of Medicine/VA Connecticut, West Haven, CT, 2Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, 3University of Turin, Torino, Turin, Italy, 4Northwell Health, Brooklyn, NY, 5IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 6NYU School of Medicine, New York, NY, 7University of Utah and Intermountain Healthcare, Salt Lake City, UT, 8University of Brescia, Brescia, Italy, 9Johns Hopkins University School of Medicine, Timonium, MD, 10Hospital Clinic de Barcelona, Barcelona, Spain, 11University of Michigan, Ann Arbor, MI, 12IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, 13University College London Hospitals NHS Foundation Trust, London, United Kingdom, 14University of Texas Medical Branch, Galveston, TX, 15King's College London, London, United Kingdom, 16Yale School of Medicine, New Haven, CT, 17Hospital for Special Surgery, New York, NY

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thromboembolic and obstetric morbidity arising via a model of immunothrombosis. Patients may present with thrombotic (tAPS),…
  • Abstract Number: 0129 • ACR Convergence 2024

    The Efficacy and Safety of Telitacicept Following Rituximab Immunotherapy on Antiphospholipid Syndrome, a Prospective 24- Week Study

    Qiang Shu1, Qing Zuraw2, Xiaoyu Zhang3, Guillermo Pons-Estel4, Shuning Sun5, Qincheng Che1, Xinyu Li6, Jie Li6 and Qi Liu6, 1Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan, China; Qilu Hospital, Cheeloo College of Medicine, Shandong University, Rheumatology, Jinan, China, Jinan, China (People's Republic), 2RemeGen Biosciences, Inc., South San Francisco, China (People's Republic), 3Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan China, Beijing, China, 4Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, 5Qilu Hospital, Shandong Provincial Clinical Research Center for Immune Disease and Gout, Jinan, China; Qilu Hospital, Cheeloo College of Medicine, Shandong University, Pheumatology, Jinan, China, Jinan, China (People's Republic), 6Qilu Hospital, Jinan, China (People's Republic)

    Background/Purpose: Antiphospholipid syndrome (APS) is a challenging disease to treat and lack effective therapies. Rituximab (RTX) can deplete CD20+ peripheral B cells. Telitacicept (TA) is…
  • Abstract Number: 2391 • ACR Convergence 2024

    Identification of Patients with ANA Negative and Double Stranded DNA Positive: What Is the Significance in Daily Rheumatology Practise

    Güllü Sandal Uzun1, Emily Apsley2 and David Isenberg2, 1University College London, London, England, United Kingdom, 2University College London, London, United Kingdom

    Background/Purpose: The anti-nuclear antibody (ANA test)  is a sensitive screening tool used when assessing patients with possible autoimmune rheumatic diseases (ARD). Homogeneous staining positivity is…
  • Abstract Number: 0098 • ACR Convergence 2024

    Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus

    Marina Barguil Macedo1, Jorge Armando Gonzalez-Chapa1, Anders Bengtsson2, Iva Gunnarsson3, Elisabet Svenungsson4 and Christian Lood1, 1University of Washington, Seattle, WA, 2Lund University, Lund, Sweden, 3Karolinska Institute, Stockholm, Sweden, 4Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Heat shock protein 90 alpha (HSP90α) is an epichaperone present ubiquitously inside the cell, whose dimers function as a foldase that helps the correct…
  • Abstract Number: 0114 • ACR Convergence 2024

    Rare Germline Variants in Complement Regulatory Genes in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Cécile Yelnik1, shruti chaturvedi2, Julien Labreuche3, Xiang-Zuo Pan2, H Michael Belmont4, Nina Kello5, Paul Fortin6, David Branch7, Yu Zuo8, Rohan Willis9, Robert Brodsky2, Jane Salmon10, Maria Laura Bertolaccini11, Hannah Cohen12, Michelle Petri13 and Doruk Erkan10, and on behalf of APS ACTION, 1lille university, Lille, France, 2John Hopkins University, Baltimore, MD, 3Lille University Hospital, Lille, France, 4NYU Langone Health, New York, NY, 5Northwell Health, Brooklyn, NY, 6Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 7University of Utah and Intermountain Healthcare, Salt Lake City, UT, 8University of Michigan, Ann Arbor, MI, 9University of Texas Medical Branch, Galveston, TX, 10Hospital for Special Surgery, New York, NY, 11King's College London, London, United Kingdom, 12University College London Hospitals NHS Foundation Trust, London, United Kingdom, 13Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: We previously reported that markers of complement activation, specifically elevated C4d levels and positive modified HAM (mHAM) test, are associated with a higher risk…
  • Abstract Number: 0451 • ACR Convergence 2024

    Macrophages and Interferon Upregulation in Placentas from Patients with Systemic Lupus Erythematosus, Primary Sjögren’s Disease and Antiphospholipid Syndrome

    Juan J. Fierro1, Mirthe Schoots1, Silvia Liefers1, Berber Doornbos-van der Meer2, Gilles Diercks1, Hendrika Bootsma3, Jelmer R. Prins1, Johanna Westra1 and Karina de Leeuw4, 1University Medical Center Groningen, University of Groningen, Groningen, Groningen, Netherlands, 2University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 3Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, 4University Medical Center Groningen, Groningen, Groningen, Netherlands

    Background/Purpose: SLE, primary Sjögren’s disease (pSjD) and APS are systemic rheumatic diseases (SRD) that mainly affect women of childbearing age and have been associated with…
  • Abstract Number: 2535 • ACR Convergence 2024

    The Lipidomic and Proteomic Profiles in Antiphospholipid Syndrome Patients Are Intricately Linked to Disease Pathogenesis and Modulated by Ubiquinol Supplementation

    Chary Lopez-Pedrera1, Beatriz Vellón-García2, Mª Angeles Aguirre-Zamorano3, Sagrario Corrales4, Ismael Sánchez Pareja4, Laura Muñoz-Barrera4, Tomás Cerdó4, Pedro Segui5, Christian Merlo5, María del carmen ábalos-Aguilera5, Nuria Barbarroja4, Alejandro Escudero-Contreras6, Rafaela Ortega-Castro7, José Manuel Villalba8 and Carlos Perez-Sanchez4, 1IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 2Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA3) / Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, 3IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, 4IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 5Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, 6Reina Sofia University Hospital, Córdoba, Spain, 7Hospital Reina Sofía, Cordoba, Andalucia, Spain, 8Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA3), Cordoba, Spain

    Background/Purpose: This study aims to:1) Characterize the circulating lipidomic and proteomic profiles of APS patient and analyse its association with clinical features.2) Investigate the short-term…
  • Abstract Number: 0099 • ACR Convergence 2024

    Modulating Pentose Phosphate Pathway Metabolism to Temper Neutrophil Hyperactivity in Antiphospholipid Syndrome

    Kaitlyn Sabb1, Ajay Tambralli1, Megan Radyk1, Emily Becker1, Srilakshmi Yalavarthi1, Claire Hoy1, Cyrus Sarosh2, Jacqueline Madison1, Yu Zuo1, Costas Lyssiotis1 and Jason Knight1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Temperance, MI

    Background/Purpose: Neutrophil hyperactivity and neutrophil extracellular trap (NET) release (NETosis) appear to play important roles in antiphospholipid syndrome (APS) pathogenesis. To kill microbes and propel…
  • Abstract Number: 0115 • ACR Convergence 2024

    Regional and Ethnoracial Differences Among Antiphospholipid Antibody-Positive Patients with No Other Systemic Autoimmune Rheumatic Diseases: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Registry

    Elena Gkrouzman1, Ann E. Clarke2, Maria Tektonidou3, Vittorio Pengo4, Savino Sciascia5, Jose Pardos-Gea6, Nina Kello7, Diana Paredes-Ruiz8, Mª Angeles Aguirre-Zamorano9, H Michael Belmont10, Paul Fortin11, Guilherme Ramires de Jesús12, Tatsuya Atsumi13, Zhuoli Zhang14, Maria Efthymiou15, David Branch16, Giulia Pazzola17, Laura Andreoli18, Ali Duarte-Garcia19, Esther Rodriguez-Almaraz20, Michelle Petri21, Ricard Cervera22, Bahar Artim Esen23, Guillermo Pons-Estel24, Hui Shi25, Jason Knight26, Rohan Willis27, Pierluigi Meroni28, Maria Laura Bertolaccini29, Hannah Cohen30, Robert Roubey31, Danieli Andrade32 and Doruk Erkan33, and on behalf of APS ACTION, 1University of Massachusetts, Westborough, MA, 2Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 3National and Kapodistrian University of Athens, Athens, Greece, 4Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, 5University of Turin, Torino, Turin, Italy, 6Vall d'Hebron University Hospital, Barcelona, Spain, 7Northwell Health, Brooklyn, NY, 8Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, 9IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, 10NYU School of Medicine, New York, NY, 11Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 12Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 13Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, 14Peking University First Hospital, Beijing, China, 15University College London, London, United Kingdom, 16University of Utah and Intermountain Healthcare, Salt Lake City, UT, 17Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, 18University of Brescia, Brescia, Italy, 19Mayo Clinic, Rochester, MN, 20Hospital Universitario 12 de Octubre, Madrid, Spain, 21Johns Hopkins University School of Medicine, Timonium, MD, 22Hospital Clinic de Barcelona, Barcelona, Spain, 23Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 24CREAR, Rosario, Argentina, 25Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic), 26University of Michigan, Ann Arbor, MI, 27University of Texas Medical Branch, Galveston, TX, 28IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, 29King's College London, London, United Kingdom, 30University College London Hospitals NHS Foundation Trust, London, United Kingdom, 31Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 32University of São Paulo, São Paulo, SP, Brazil, 33Hospital for Special Surgery, New York, NY

    Background/Purpose: The APS ACTION Registry was created to study long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with and without other systemic autoimmune rheumatic diseases…
  • Abstract Number: 0639 • ACR Convergence 2024

    Delayed Diagnosis in Systemic Lupus Erythematosus

    Romina Nieto1, Lucia Hernandez2, Nidia Noemí Merás3, Bordón Florencia Juliana4, Cintia Otaduy5, Lucila Garcia6, Rosa Serrano Morales7, Nicolás Pérez8, Micaela A. Cosatti9, Ana Carolina Montandon10, Gustavo Flores Chapacais11, Laissa C. Alves Alvino12, Emily Figuereido Neves13, Eloisa Bonfa14, Alexis Bondi Peralta15, Loreto Massardo16, Andrés Cadena Bonfanti17, Andrés Hormaza18, José Martínez19, Olga Lidia Vera Lastra20, Hilda Fragoso-Loyo21, ⁠Yaneli Juárez-Vicuña22, Diana Fernandez23, Patricia Langjarth24, Maria Teresa Martinez de Filartiga25, Manuel Ugarte-Gil26, Carlos Alejandro Loayza Flores27, Teresandris Polanco28, Maria Belen Lecumberri29, Álvaro Danza30, Carlos Enrique Toro-Gutierrez31, Urbano Sbarigia32, Ashley Orillion33, Federico Zazzetti34, Graciela Alarcon35, Bernardo Pons-Estel2 and Guillermo Pons-Estel36, and Grupo Latino Americano de Estudio del Lupus (GLADEL), 1Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, 3Hospital Italiano de Córdoba, Cordoba, Argentina, 4Hospital Privado Universitario de Córdoba, Córdoba, Argentina, 5Hospital Córdoba, Cordoba, Spain, 6Servicio de Reumatología del HIGA San Martín, La Plata, Argentina, 7Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, 8Instituto de Investigaciones Médicos Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, 9CEMIC Centro de Educación Médica e Investigaciones Clínicas ''Norberto Quirno'' CABA, CABA, Argentina, 10Hospital das Clinicas, Universidad Federal de Goias, Goias, Brazil, 11Rheumatology Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 12Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, 13Hospital da Clinicas de Sao Paulo, São Paulo, SP, Brazil, 14Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 15Hospital del Salvador, Santiago, Chile, 16Centro de Biología Celular y Biomedicina CEBICEM, Facultad de Medicina y Ciencias Universidad San Sebastián, Santiago, Chile, 17Universidad Simon Bolivar, Barranquilla, Colombia, 18Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, 19Rheumatology Service, Luís Vernaza Hospital, Guayaquil, Ecuador, 20División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, 21Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, 22Instituto Nacional de Cardiología Ignacio Chávez, Departamento de Inmunología, Investigador en Ciencias Médicas C, Mexico City, Mexico, 23Member of GLADEL, Rosario, Argentina, 24Hospital de Clínicas I, Asunción, Paraguay, 25Dpto de Reumatología Hospital de Clínicas. Facultad de Ciencias medicas.Universidad Nacional de Asunción, Asuncion del Paraguay, Paraguay, 26Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, 27Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, 28Hospital Docente Padre Billini, Santo Domingo, Dominica, 29Hospital Señor del Milagro, Salta, Argentina, 30Médica Uruguaya Corporación de Asistencia Médica (MUCAM). Clínica Médica - Facultad de Medicina - UdelaR, Montevideo, Uruguay, 31Reference Center for Osteoporosis & Rheumatology, Cali, Colombia, 32Johnson & Johnson Innovative Medicine, Brussels, Belgium, 33Johnson & Johnson Innovative Medicine, Spring House, PA, PA, 34Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 35The University of Alabama at Birmingham, Oakland, CA, 36Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina

    Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease of unknown etiology. Diagnosis is often delayed because it frequently mimics symptoms of other diseases;…
  • Abstract Number: 0100 • ACR Convergence 2024

    Association Between the Active Form of Plasminogen Activator Inhibitor 1 (PAI-1) and Endothelial Cell Activation in Antiphospholipid Syndrome

    Yuzhou Gan1, Wenying Liang2, Mark Warnock3, Srilakshmi Yalavarthi2, Cyrus Sarosh4, Ajay Tambralli2, Jacqueline Madison2, Yu Zuo2, Daniel Lawrence3 and Jason Knight2, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI, 3Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, 4University of Michigan, Temperance, MI

    Background/Purpose: Plasminogen activator inhibitor 1 (PAI-1), a SERPIN-type inhibitor, is best known for regulating fibrinolysis, where it inhibits the activity of tissue and urokinase plasminogen…
  • Abstract Number: 0116 • ACR Convergence 2024

    Assessment of Triple Antiphospholipid Antibody-positive Patients Based on Clinical and Laboratory Domains of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria

    Reyhan Kose Cobanoglu1, Joann Vega2, Crystal Burgos3 and Doruk Erkan4, 1Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, 2Hospital for Special Surgery, New York, NY, New York, NY, 3Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, New York, NY, 4Hospital for Special Surgery, New York, NY

    Background/Purpose: Triple aPL-positive (lupus anticoagulant test [LA], anticardiolipin antibody (aCL), and anti-β2 glycoprotein-I antibody [aβ2GPI]) patients are at higher risk to develop a  severe clinical…
  • 1
  • 2
  • 3
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology